Skip to search formSkip to main contentSkip to account menu

pamiteplase

Known as: 275-L-Glutamic Acid-(1-91)-(174-527)-Plasminogen Activator (Human Tissue-Type Protein Moiety) 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2011
2011
An in-vitro thrombolytic model was used to check the clot lysis effect of four herbal extracts viz., Honey, Nigella sativa… 
Review
2008
Review
2008
First generation thrombolytics (streptokinase and urokinase) had no fibrin binding capabilities and caused systemic plasminogen… 
2003
2003
Abstract Using a rat model of thromboembolic stroke we evaluated whether or not fibrinolysis by bolus injection of pamiteplase, a… 
2001
2001
The effects of alteplase (tissue plasminogen activator, t-PA) and pamiteplase (a modified t-PA with longer half-life and… 
Review
2000
Review
2000
  • M. Verstraete
  • The American journal of medicine
  • 2000
  • Corpus ID: 1033227
2000
2000
1. An enzyme-linked immunosorbent assay (ELISA) and functional bioassay to determine immunoreactive and bioactive concentrations… 
2000
2000
The pharmacokinetics of pamiteplase in rats was compared with the pharmacokinetics of recombinant wild-type tissue-type… 
2000
2000
1. Differences in receptor-mediated endocytosis kinetics between pamiteplase, an engineered t-PA, and an unmodified rt-PA were… 
1997
1997
Single and repeated intravenous toxicity studies of Pamiteplase (genetical recombination) YM866, a novel recombinant human tissue…